Webinar series - Current topics in Alzheimer's disease diagnostics
We have been hosting a series of 3 webinars with leading expert speakers and dedicated to current topics in the field of Alzheimer's Disease diagnostics.
> Sign up to get notified about future webinars
The topics that were discussed in this webinar series were:
October 27th 2021 - [watch webinar replay]
CSF-based biomarkers to support the diagnosis of Alzheimer’s disease
- Daniel Alcolea - Faculty Neurologist, Sant Pau Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain:
"Positioning of the core CSF biomarkers of Alzheimer’s disease: a clinician’s perspective”
- Piotr Lewczuk - Professor of Neurochemistry and Head, Laboratory for Clinical Neurochemistry and Neurochemical Dementia Diagnostics, Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, Germany:
"Value of the β-Amyloid ratio and other CSF biomarkers in the Erlangen Score interpretation algorithm”
November 17th 2021 - [watch webinar replay]
Preparing for the future of blood-based biomarker testing in Alzheimer's disease
- Oskar Hansson - Professor of Neurology, Lund University and Senior Consultant Neurologist, Memory Clinic, Lund University and Memory Clinic, Skåne University Hospital, Lund, Sweden:
“Is plasma pTau ready for implementation in clinical practice?”
- Manu Vandijck - Product Development Manager, Fujirebio Europe, Gent, Belgium:
“Lumipulse G pTau 181 in plasma: where are we today?”
December 15th 2021 - [watch webinar replay]
Possible applications for novel CSF biomarkers
- Lucilla Parnetti (moderator) - Professor of Neurology and Head, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Italy
- Lorenzo Gaetani - Clinical Research Fellow, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Italy:
“The potential diagnostic and prognostic value of CSF NfL in different CNS disorders”
- Charlotte Teunissen - Professor of Neurochemistry and Head, Neurochemistry Lab, Amsterdam UMC, The Netherlands:
“Capturing the full complexity of Alzheimer’s disease biomarkers used in trials"
As a Neurologist of the Sant Pau Memory Unit, he has, during the last 10 years, gained clinical expertise in the diagnosis and treatment of patients with memory problems. His main research interests are the discovery and implementation of fluid biomarkers for the early and accurate diagnosis of neurodegenerative diseases. His studies have significantly contributed to this field and are reflected in numerous publications in high impact journals. He combines clinical research with academic responsibilities as a Clinical Associate in the Faculty of Medicine at the Autonomous University of Barcelona.
For more than 20 years he has been working on diagnostic and research aspects of cerebrospinal fluid, including a large panel of neurologic and psychiatric disorders, with a particular scope on neurodegenerating conditions, like Alzheimer’s disease. In 2004 he obtained the Certificate of Expertise from the German Society of Clinical Neurochemistry and currently he is a member of the Extended Board of the same society.
Responsible for the outpatient ward of the Memory Clinic at Skåne University Hospital and co-director of the strategic research area of neuroscience at Lund University. During the last 15 years, he has performed outstanding clinical and translational research that has been instrumental for the implementation of cerebrospinal fluid biomarkers in the clinical work-up of Alzheimer’s disease in Sweden and internationally. With the BioFINDER study, he focuses on the development of diagnostic algorithms for early diagnosis that include blood-based biomarkers.
She has wide experience in the field of neurodegenerative disease research, and her activity includes clinical characterization of patients with dementia and research on biomarker discovery and validation. Her main expertise is in the field of cerebrospinal fluid biomarkers for early diagnosis of neurodegenerative diseases, with special interest in Alzheimer’s disease and Parkinson’s disease.
Expert in the field of fluid biomarkers in inflammatory and degenerative diseases of the central nervous system, such as multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease, with an interest on the potential pathophysiological implications of cerebrospinal fluid biomarkers research in these diseases. His research activity focuses on the potential clinical diagnostic and prognostic application of neuronal injury biomarkers as well as in the characterization of immunological markers both in autoimmune and degenerative neurological diseases.
Her drive is to improve care of patients with neurological diseases by developing body fluid biomarkers for diagnosis, stratification, prognosis and monitoring treatment responses. Studies of her research group span the entire spectrum of biomarker development, from biomarker identification to extensive clinical validation and implementation in clinical practice. She is responsible for the large well characterized biobank of the Amsterdam Dementia cohort, containing >5200 paired CSF and serum samples. She also leads several collaborative international biomarker networks.
Joined Innogenetics (today Fujirebio Europe) in 1996 and played a pioneering role in the development of the world’s first cerebrospinal fluid-based assays for biomarker detection as an aid in the diagnosis of Alzheimer’s disease. As product development manager, he continues to play an essential part in the development of new diagnostic pathways and partnerships for neurodegeneration diagnostics at Fujirebio today. He has participated in several international consortia and working groups aiming for a better and more standardized diagnosis of Alzheimer’s disease.
Review and discuss current aspects and trends within the field of Alzheimer’s disease diagnostics. Each webinar will combine a clinically oriented session and a session with a more (post)analytical perspective.
This should provide inspiration for any healthcare professionals involved in Alzheimer’s disease research or patient management today, regardless of whether they work with biomarker testing or not.
Who should attend
- Laboratory professionals
- Healthcare professionals working with Alzheimer’s
By signing up for the webinar series today, you make sure to be kept informed first about the practical details, speaker information and presentation topics for each webinar, as soon as these are available.
In case you miss one of our webinars - this happens - we will also be sending you a link to the replay for reviewing at your convenience.